$984.69
-$5.85 (-0.59%)
$982.25Day Range$1000.59
Key Statistics
Market Cap
$61.97B
Shares Outstanding
62.6M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
May 18, 2017
Round Lot
40
Locale
US
Trading Data
Day Open
$985.87
Day High
$1000.59
Day Low
$982.25
Volume
119.6K
VWAP
$990.35
Prev Close
$990.54
Transactions
--
Acc. Volume
--
About argenx SE American Depositary Shares
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Identifiers
- CIK
- 0001697862
- Composite FIGI
- BBG00GHB88X9
- Share Class FIGI
- BBG00GHB88Y8
- Ticker Root
- ARGX
About argenx SE American Depositary Shares (ARGX) Stock
argenx SE American Depositary Shares (ARGX) closed the 2026-09-15 session at $984.69, down 0.59% versus the previous close (-5.85). The stock opened at $985.87 and traded between $982.25 and $1000.59 during that session. Session trading volume was 120K shares. The volume-weighted average price (VWAP) is $990.35.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
argenx SE American Depositary Shares has a market capitalization of $61.97 billion. ARGX is listed on the XNAS exchange. The company employs approximately 1,863 people. The recorded listing date is 2017-05-18.
On this page you can find market ARGX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.